Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JHPCYNext catalyst
SHR-A1811 combined with Pyrotinib
HER2-expressing Advanced Solid Tumors
Get an email about JHPCY's next catalysts
Track Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 39 more upcoming events in our data (Phase 2 readout, Phase 3 readout, PDUFA date).See the timeline
40 upcoming, 1 past
SHR-A1811 combined with Pyrotinib Phase 2 Est. Readout
Estimated primary completion for SHR-A1811 combined with Pyrotinib trial (NCT06015048) in HER2-expressing Advanced Solid Tumors. Topline data typically follows completion by weeks to months.
SourceBupivacaine Liposome Injection Phase 2 Est. Readout
Estimated primary completion for Bupivacaine Liposome Injection trial (NCT06529432) in Local Analgesia Via Nerve Block. Topline data typically follows completion by weeks to months.
SourceCamrelizumab plus apatinib CohortA Phase 2 Est. Readout
Estimated primary completion for Camrelizumab plus apatinib CohortA trial (NCT05139095) in Gestational Trophoblastic Neoplasia. Topline data typically follows completion by weeks to months.
SourceSHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 Phase 2 Est. Readout
Estimated primary completion for SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 trial (NCT05482568) in Advanced Non-small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceHRS-6209 Capsules Phase 2 Est. Readout
Estimated primary completion for HRS-6209 Capsules trial (NCT06974929) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourceLutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide Phase 3 Est. Readout
Estimated primary completion for Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide trial (NCT05884255) in Advanced Gastroenteropancreatic Neuroendocrine Tumor. Topline data typically follows completion by weeks to months.
SourceHepatectomy Combined With Camrelizumab and Apatinib Phase 3 Est. Readout
Estimated primary completion for Hepatectomy Combined With Camrelizumab and Apatinib trial (NCT05062837) in Hepatocellular Carcinoma. Topline data typically follows completion by weeks to months.
SourceSHR-A1811 Phase 2 Est. Readout
Estimated primary completion for SHR-A1811 trial (NCT06413745) in HER2 Expression / Amplification in Patients With Biliary Tract Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Remimazolam Tosilate for injection
Operative Sedation of Pediatric
Hetrombopag Olamine
Severe Aplastic Anemia
SHR0302
Rheumatoid Arthritis
FH-006
Malignant Solid Tumor
SHR7280；Ganirelix Acetate Injection simulant
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
TACE+Camrelizumab+Apatinib mesylate
Hepatocellular Carcinoma
Remimazolam Tosilate
General Anesthesia
HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
Colorectal Cancer
SHR2554; Chidamide analog tablets
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Hetrombopag
Chemotherapy-Induced Thrombocytopenia
SHR-1316、Chemotherapeutic
Non-Small-Cell Lung Cancer
HRS-4357 injection
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Propofol
Anesthesia for Elective Surgery Patients
capecitabine + camrelizumab + apatinib
Breast Cancer
JSKN003
Advanced Solid Tumor
Fluzoparib capsules
Ovarian Cancer
Pyrotinib in combination with Capecitabine
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Paclitaxel Injection
Ovarian Cancer
SHR8058 eye drops
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
SHR4640
Gout
SHR8028 eye drops
Dry Eye Disease
HRS-9190
Neuromuscular Blockade
Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Breast Cancer
Camrelizumab Plus Chemotherapy
Triple Negative Breast Cancer
Propofol Medium and Long Chain Fat Emulsion Injection
Sedation in the ICU
JSKN016 Injection
Triple Negative Breast Cancer
SHR7280 tablets
Uterine Fibroids With Menorrhagia
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate
First-line Treatment of Metastatic Pancreatic Cancer
Noiiglutide Injection
Type 2 Diabetes
SHR-A1811
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Almonertinib
Non-small Cell Lung Cancer
Capecitabine tablets
Breast Cancer
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin
Non-Small-Cell Lung Cancer
camrelizumab； famitinib malate
Cervical Cancer
SHR-1209
Primary Hypercholesterolemia
Rivoceranib (Apatinib)
Hepatocellular Carcinoma (HCC)
dexmedetomidine hydrochloride nasal spray
Preoperative Sedation
BP102, paclitaxel, carboplatin
Non-small Cell Lung Cancer(NSCLC)
Paracetamol injection
Post-operative Analgesia
X0002 Spray
KNEE OSTEOARTHRITIS
PD-1 blocking antibody
Nasopharyngeal Carcinoma
Irinotecan liposome、5-Fluorouracil、Leucovorin
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
HRS-4642 + AG
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Pyrotinib
HER2-positive Breast Cancer
apatinib
Non-Small-Cell Lung Cancer
HR17031 injection
Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
Rezvilutamide Tablets
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
SHR-A1811 for Injection
Early-stage or Locally Advanced HER2-positive Breast Cancer
Camrelizumab plus TP
Oral Squamous Cell Carcinoma
SHR6390
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
Apatinib Mesylate
Hepatocellular Carcinoma
SHR-1210
Nasopharyngeal Carcinoma
SHR-A1811 Injection ； Pertuzumab Injection
HER2-PositiveRecurrent or Metastatic Breast Cancer
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Breast Cancer Invasive
SHR4640 dose2
Gout
SHR8554 Injection
Pain
INS068 injection
Type 2 Diabetes Mellitus
Fuzuloparib, Abiraterone acetate and Prednisone
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
68Ga-DOTATOC
Advanced Gastroenteropancreatic Neuroendocrine Tumor
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
First-line Treatment of Advanced Pancreatic Cancer
Rocuronium
Neuromuscular Blockade
SHR-A1811 Injection
Recurrent or Metastatic Cervical Cancer
Camrelizumab
Hepatocellular Carcinoma
Ramucirumab/Paclitaxel/Docetaxel/Irinotecan
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
HRS-8427
Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
SHR0410 Injection
Pain
SHR3680
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
SHR4640 dose1
Gout
camrelizumab combined with rivoceranib and HAIC
Potentially Resectable Hepatocellular Carcinoma
Hetrombopag Olamine+Standard Therapy
Severe Aplastic Anemia
Herombopag tablets
Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Pegylated rhG-CSF
Breast Cancer
Camrelizumab、Pemetrexed/Paclitaxel、Carboplatin/Cisplatin
Non-Small Cell Lung Cancer With HER2- Mutations
Hepatectomy Combined With Camrelizumab and Apatinib
Hepatocellular Carcinoma
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Morhpine PCA
Post-operative Analgesia
SHR2554 analog tablets; Chidamide
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Tegileridine Fumarate lnjection
Abirritation in the ICU
SHR4640 ；Febuxostat
Primary Gout and Hyperuricemia
HRS-6209 in Combination with HRS-1358
Advanced Unresectable or Metastatic Breast Cancer
HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab
Advanced Unresectable or Metastatic Breast Cancer
Fluzoparib Combined With Apatinib
Metastatic Castration Resistant Prostate Cancer
HRS-6209 in Combination with HRS-9813 and HRS-8080
Advanced Unresectable or Metastatic Breast Cancer
Apatinib and Adebrelimab in Combination With chemotherapy
Intrahepatic Cholangiocarcinoma (Icc)
HRS-6209 in Combination with Letrozole
Advanced Unresectable or Metastatic Breast Cancer
HRS-6209 in Combination HRS-4508 and letrozole
Advanced Unresectable or Metastatic Breast Cancer
SHR-1210+GEMOX
Biliary Tract Cancer
entinostat
Breast Cancer
docetaxel,0xaliplatin,capecitabine
Gastric Cancer
Camrelizumab+Fluzoparib
Germline BRCA-mutated HER2-negative Breast Cancer
Epirubicin
Breast Cancer
Camrelizumab and Apatinib Plus GP
Locally Advanced Biliary Tract Cancer
NALIRIFOX+Adebrelimab
Pancreatic Ductal Adenocarcinoma (PDAC)
Adebrelimab
Metastatic Colorectal Cancer
Lenvatinib
Intrahepatic Cholangiocarcinoma
HRS-4642
Pancreatic Cancer
Rezvilutamide
Prostate Cancer
HRS-6209 in Combination with HRS-9813 and Letrozole
Advanced Unresectable or Metastatic Breast Cancer
HRS-6209 in Combination with HRS-8080
Advanced Unresectable or Metastatic Breast Cancer
HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab
Advanced Unresectable or Metastatic Breast Cancer
HRS-6209 in Combination with letrozole and trastuzumab
Advanced Unresectable or Metastatic Breast Cancer
Famitinib Malate
Breast Neoplasms
SHR-A2102 or/and HRS-4642
Pancreatic Cancer
Taxane Chemotherapy
HER2 + Breast Cancer
HRS-4642+AG
Pancreatic Cancer
SHR6390+anatrozole
Breast Cancer
Abiraterone Acetate Tablets (I)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
irinotecan liposome (II) + temozolomide + fluzoparib
Ewing Sarcoma
Camrelizumab plus apatinib CohortA
Gestational Trophoblastic Neoplasia
Adebrelimab combined with Apatinib
SCLC
Camrelizumanb plus TPF
Oral Squamous Cell Carcinoma
Apatinib+IE
Effect of Drug
Neoadjuvant Chemotherapy
Esophageal Squamous Cell Carcinoma
Mecapegfilgrastim
Metastatic Breast Cancer
Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
Breast Cancer
EC chemotherapy
Breast Cancer Invasive
HRS-4642+AG +Adebrelimab
Pancreatic Cancer
COPOX
Gastric Cancer (GC)
Mecapegfilgrastim, day 2
Multiple Myeloma
Radiation
Esophageal Neoplasms
TACE with adebrelimab and bevacizumab
Adebrelimab
Cetuximab Solution for Infusion
Advanced KRAS G12D Mutant Solid Tumors
SHR-9839
Advanced KRAS G12D Mutant Solid Tumors
HRS-4508+ Trastuzumab+ Pertuzumab
Solid Tumor
HRS-4508+ Trastuzumab + Nab-paclitaxel
Solid Tumor
HRS-4508+SHR-A1811
Solid Tumor
HRS-2189 Tablets
Breast Cancer
SHR2554; SHR-1701
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Mecapegfilgrastim, day 5
Multiple Myeloma
Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection
Advanced KRAS G12D Mutant Solid Tumors
Fluzoparib
Metastatic Castration Resistant Prostate Cancer
HRG2010(II)
Parkinson's Disease
• Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
Esophageal Squamous Cell Carcinoma (ESCC)
HRS-9190; under Intravenous Anesthesia
Neuromuscular Blockade
HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel
Solid Tumor
HRS-4508+ Trastuzumab+ Capecitabine
Solid Tumor
Letrozole Tablets
Breast Cancer
SHR2554; Adabelimumab
Locally Advanced or Metastatic Non-small Cell Lung Cancer
HRS-4508+ Trastuzumab
Solid Tumor
Immunotherapy
Esophageal Squamous Cell Carcinoma
Pyrotinib Maleate
Breast Neoplasms
SHR4640 ; Febuxostat
Primary Gout and Hyperuricemia
Herombopag
Non Severe Aplastic Anemia
SHR-A1811 Injection + Adebrelimab Injection
HR Positive/HER2 Low Breast Cancer
Doxorubicin Hydrochloride Liposome Injection
Breast Cancer
Dalpiciclib Isethionate Tablets
Breast Neoplasms
FH-006 for Injection
Malignant Solid Tumor
SHR-8068
Pancreatic Cancer
Docetaxel Injection
Prostate Cancer
SHR2554 tablets
Prostate Cancer
SHR-A1904 Injection
Advanced Gastric Cancer
Abiraterone Acetate tablets（II）
Prostate Cancer
Prednisone Acetate tablets
Prostate Cancer
HRS-6208 capsules
Prostate Cancer
SHR-1701 Injection
Advanced Gastric Cancer
SHR-1316
Small Cell Lung Cancer
SHR0302 Base Gel
Non-segmental Vitiligo
Dalpiciclib
Breast Cancer
exemestane, fulvestrant, letrozole, tamoxifen
Metastatic Breast Cancer
SHR-A1811 combined with other antitumor therapies
HER2-expressing Advanced Solid Tumors
Camrelizumab plus apatinib Cohort B
Gestational Trophoblastic Neoplasia
SHR-1316 Injection
Malignant Solid Tumor
Letrozole or anastrozole or Fulvestrant
Advanced Breast Cancer
Inetetamab
Breast Neoplasms
GEMOX
Advanced Primary Liver Cancer
CAPOX
CRC (Colorectal Cancer)
Bupivacaine Liposome Injection
Local Analgesia Via Nerve Block
SHR-A1904 or/and HRS-4642
Pancreatic Cancer
SHR-A2102, HRS4642 and Adebrelimab
Pancreatic Cancer
SHR-A1811 or/and HRS-4642
Pancreatic Cancer
Propofol Injection
Local Anesthesia Assisted Sedation
RSS0343 Tabella
Adolescent Asthma
SHR-1020
Recurrent or Metastatic Cervical Cancer
SHR-3167 Injection
Diabetes Mellitus, Type 2
HRS-4508+ Capecitabine
Solid Tumor
SHR2554/CHOP
Peripheral T-cell Lymphoma
SP2086/Metformin
Type 2 Diabetes
Retlirafusp alfa Injection
CRC (Colorectal Cancer)
KN019
Rheumatoid Arthritis
HR18042
Moderate to Severe Acute Pain
KN026
Gastric/Gastroesophageal Junction Cancer
SHR-1701
Pancreatic Cancer
SHR117887
Type 2 Diabetes
FOLFOX4
Advanced Primary Liver Cancer
FH-006; SHR-1316 ; SHR-8068
Lung Cancer
Abiraterone Tablet
Prostate Cancer
SS109
Male
SHR2554 Tablet
Prostate Cancer
Darotamine Capsule
Prostate Cancer
FH-006 ; SHR-1316 ; BP102
Lung Cancer
SHR3680 Tablet
Prostate Cancer
HRS-1167 tablets
Prostate Cancer
HRS4800 tablets
Pain
Fluzoparib+Apatinib
Relapsed Ovarian Cancer
HR19042 Capsules
IgA Nephropathy
FRSW117
Severe Hemophilia A
HRS-4508 tablet
Lung Cancer
Famitinib
Colorectal Cancer
HRG2010(I)
Parkinson's Disease
SHR0302 Tablets
Non-segmental Vitiligo
APL-1202 treatment
Non-muscle Invasive Bladder Cancer
KN026 combination
HER2-positive Solid Tumors
mFOLFIRINOX
Advanced Pancreatic Cancer
HS-20093 for Injection
Prostate Cancer
benzbromarone
Hyperuricemia
JSKN016
Inoperable Locally Advanced HER2-Negative Breast Cancer
HS-20004
Diabetes Mellitus, Type 2
HRS-6209 Capsules
Breast Cancer
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
Lung Cancer
HR021618
Pain After Abdominal Surgery
HRS-5041 tablets
Prostate Cancer
HS-10375
Advanced or Metastatic NSCLC
HS-10365 capsules
Nonsmall Cell Lung Cancer
SHR7280
Endometriosis
SHR-A1811 combined with Pyrotinib
HER2-expressing Advanced Solid Tumors
HS-20094
Type 2 Diabetes
SP2086
Type 2 Diabetes
HRS-6209 in Combination with Fulvestrant
Advanced Unresectable or Metastatic Breast Cancer
SHR2554; SHR-A2102
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Insulin Degludec
Type 2 Diabetes
SHR-1703
Asthma With Eosinophilic Phenotype
mFOLFOX7 combined with Camrelizumab and apatinib
Hepatocellular Carcinoma Non-resectable
Paclitaxel for injection (albumin-bound)
Esophageal Squamous Cell Carcinoma
KN046
Esophageal Squamous Cell Carcinoma
SHR-3167
Type 2 Diabetes Mellitus
SHR 1210+apatinib
Hepatocellular Carcinoma
SHR0302Base gel
Vitiligo
SHR-A1904
Advanced Solid Tumors
HRS-6768
Advanced Solid Tumors
SHR- A1811
Gynaecological Malignancies
Meropenem
Hospital-acquired Bacterial Pneumonia (HABP)
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
Advanced Non-small Cell Lung Cancer
SHR-4394
Prostate Cancer
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Advanced Non-small Cell Lung Cancer
SHR-1314
Moderate-to-severe Chronic Plaque Psoriasis
HR020602 injection
Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)
HRS-6213
Patients With Solid Tumors
Camrelizumab、Rivoceranib
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
HRS-9190; under Inhalational Anesthesia
Neuromuscular Blockade
HRS-8364 Tablet
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Remimazolam Tosilate for injection | Phase 3 | Operative Sedation of Pediatric | - | - |
Hetrombopag Olamine | Phase 3 | Severe Aplastic Anemia | - | - |
SHR0302 | Phase 3 | Rheumatoid Arthritis | - | - |
FH-006 | Phase 3 | Malignant Solid Tumor | - | - |
SHR7280；Ganirelix Acetate Injection simulant | Phase 3 | Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation | - | - |
TACE+Camrelizumab+Apatinib mesylate | Phase 3 | Hepatocellular Carcinoma | - | - |
Remimazolam Tosilate | Phase 3 | General Anesthesia | - | - |
HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab | Phase 3 | Colorectal Cancer | - | - |
SHR2554; Chidamide analog tablets | Phase 3 | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | - | - |
Hetrombopag | Phase 3 | Chemotherapy-Induced Thrombocytopenia | - | - |
SHR-1316、Chemotherapeutic | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
HRS-4357 injection | Phase 3 | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer | - | - |
Propofol | Phase 3 | Anesthesia for Elective Surgery Patients | - | - |
capecitabine + camrelizumab + apatinib | Phase 3 | Breast Cancer | - | - |
JSKN003 | Phase 3 | Advanced Solid Tumor | - | - |
Fluzoparib capsules | Phase 3 | Ovarian Cancer | - | - |
Pyrotinib in combination with Capecitabine | Phase 3 | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | - | - |
Paclitaxel Injection | Phase 3 | Ovarian Cancer | - | - |
SHR8058 eye drops | Phase 3 | Treatment of Dry Eye Disease With Meibomian Gland Dysfunction | - | - |
SHR4640 | Phase 3 | Gout | - | - |
SHR8028 eye drops | Phase 3 | Dry Eye Disease | - | - |
HRS-9190 | Phase 3 | Neuromuscular Blockade | - | - |
Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel | Phase 3 | Breast Cancer | - | - |
Camrelizumab Plus Chemotherapy | Phase 3 | Triple Negative Breast Cancer | - | - |
Propofol Medium and Long Chain Fat Emulsion Injection | Phase 3 | Sedation in the ICU | - | - |
JSKN016 Injection | Phase 3 | Triple Negative Breast Cancer | - | - |
SHR7280 tablets | Phase 3 | Uterine Fibroids With Menorrhagia | - | - |
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Metastatic Pancreatic Cancer | - | - |
Noiiglutide Injection | Phase 3 | Type 2 Diabetes | - | - |
SHR-A1811 | Phase 3 | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | - | - |
Almonertinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
Capecitabine tablets | Phase 3 | Breast Cancer | - | - |
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
camrelizumab； famitinib malate | Phase 3 | Cervical Cancer | - | - |
SHR-1209 | Phase 3 | Primary Hypercholesterolemia | - | - |
Rivoceranib (Apatinib) | Phase 3 | Hepatocellular Carcinoma (HCC) | - | - |
dexmedetomidine hydrochloride nasal spray | Phase 3 | Preoperative Sedation | - | - |
BP102, paclitaxel, carboplatin | Phase 3 | Non-small Cell Lung Cancer(NSCLC) | - | - |
Paracetamol injection | Phase 3 | Post-operative Analgesia | - | - |
X0002 Spray | Phase 3 | KNEE OSTEOARTHRITIS | - | - |
PD-1 blocking antibody | Phase 3 | Nasopharyngeal Carcinoma | - | - |
Irinotecan liposome、5-Fluorouracil、Leucovorin | Phase 3 | Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy | - | - |
HRS-4642 + AG | Phase 3 | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting | - | - |
Pyrotinib | Phase 3 | HER2-positive Breast Cancer | - | - |
apatinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
HR17031 injection | Phase 3 | Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs | - | - |
Rezvilutamide Tablets | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | - | - |
SHR-A1811 for Injection | Phase 3 | Early-stage or Locally Advanced HER2-positive Breast Cancer | - | - |
Camrelizumab plus TP | Phase 3 | Oral Squamous Cell Carcinoma | - | - |
SHR6390 | Phase 3 | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer | - | - |
Apatinib Mesylate | Phase 3 | Hepatocellular Carcinoma | - | - |
SHR-1210 | Phase 3 | Nasopharyngeal Carcinoma | - | - |
SHR-A1811 Injection ； Pertuzumab Injection | Phase 3 | HER2-PositiveRecurrent or Metastatic Breast Cancer | - | - |
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel | Phase 3 | Breast Cancer Invasive | - | - |
SHR4640 dose2 | Phase 3 | Gout | - | - |
SHR8554 Injection | Phase 3 | Pain | - | - |
INS068 injection | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Fuzuloparib, Abiraterone acetate and Prednisone | Phase 3 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - | - |
68Ga-DOTATOC | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | - | - |
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Advanced Pancreatic Cancer | - | - |
Rocuronium | Phase 3 | Neuromuscular Blockade | - | - |
SHR-A1811 Injection | Phase 3 | Recurrent or Metastatic Cervical Cancer | - | - |
Camrelizumab | Phase 3 | Hepatocellular Carcinoma | - | - |
Ramucirumab/Paclitaxel/Docetaxel/Irinotecan | Phase 3 | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | - | - |
HRS-8427 | Phase 3 | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | - | - |
SHR0410 Injection | Phase 3 | Pain | - | - |
SHR3680 | Phase 3 | Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | - | - |
SHR4640 dose1 | Phase 3 | Gout | - | - |
camrelizumab combined with rivoceranib and HAIC | Phase 3 | Potentially Resectable Hepatocellular Carcinoma | - | - |
Hetrombopag Olamine+Standard Therapy | Phase 3 | Severe Aplastic Anemia | - | - |
Herombopag tablets | Phase 3 | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | - | - |
Pegylated rhG-CSF | Phase 3 | Breast Cancer | - | - |
Camrelizumab、Pemetrexed/Paclitaxel、Carboplatin/Cisplatin | Phase 3 | Non-Small Cell Lung Cancer With HER2- Mutations | - | - |
Hepatectomy Combined With Camrelizumab and Apatinib | Phase 3 | Hepatocellular Carcinoma | - | - |
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | - | - |
Morhpine PCA | Phase 3 | Post-operative Analgesia | - | - |
SHR2554 analog tablets; Chidamide | Phase 3 | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | - | - |
Tegileridine Fumarate lnjection | Phase 2 | Abirritation in the ICU | - | - |
SHR4640 ；Febuxostat | Phase 2 | Primary Gout and Hyperuricemia | - | - |
HRS-6209 in Combination with HRS-1358 | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
Fluzoparib Combined With Apatinib | Phase 2 | Metastatic Castration Resistant Prostate Cancer | - | - |
HRS-6209 in Combination with HRS-9813 and HRS-8080 | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
Apatinib and Adebrelimab in Combination With chemotherapy | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | - | - |
HRS-6209 in Combination with Letrozole | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
HRS-6209 in Combination HRS-4508 and letrozole | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
SHR-1210+GEMOX | Phase 2 | Biliary Tract Cancer | - | - |
entinostat | Phase 2 | Breast Cancer | - | - |
docetaxel,0xaliplatin,capecitabine | Phase 2 | Gastric Cancer | - | - |
Camrelizumab+Fluzoparib | Phase 2 | Germline BRCA-mutated HER2-negative Breast Cancer | - | - |
Epirubicin | Phase 2 | Breast Cancer | - | - |
Camrelizumab and Apatinib Plus GP | Phase 2 | Locally Advanced Biliary Tract Cancer | - | - |
NALIRIFOX+Adebrelimab | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
Adebrelimab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Lenvatinib | Phase 2 | Intrahepatic Cholangiocarcinoma | - | - |
HRS-4642 | Phase 2 | Pancreatic Cancer | - | - |
Rezvilutamide | Phase 2 | Prostate Cancer | - | - |
HRS-6209 in Combination with HRS-9813 and Letrozole | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
HRS-6209 in Combination with HRS-8080 | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
HRS-6209 in Combination with letrozole and trastuzumab | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
Famitinib Malate | Phase 2 | Breast Neoplasms | - | - |
SHR-A2102 or/and HRS-4642 | Phase 2 | Pancreatic Cancer | - | - |
Taxane Chemotherapy | Phase 2 | HER2 + Breast Cancer | - | - |
HRS-4642+AG | Phase 2 | Pancreatic Cancer | - | - |
SHR6390+anatrozole | Phase 2 | Breast Cancer | - | - |
Abiraterone Acetate Tablets (I) | Phase 2 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | - | - |
irinotecan liposome (II) + temozolomide + fluzoparib | Phase 2 | Ewing Sarcoma | - | - |
Camrelizumab plus apatinib CohortA | Phase 2 | Gestational Trophoblastic Neoplasia | - | - |
Adebrelimab combined with Apatinib | Phase 2 | SCLC | - | - |
Camrelizumanb plus TPF | Phase 2 | Oral Squamous Cell Carcinoma | - | - |
Apatinib+IE | Phase 2 | Effect of Drug | - | - |
Neoadjuvant Chemotherapy | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
Mecapegfilgrastim | Phase 2 | Metastatic Breast Cancer | - | - |
Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment | Phase 2 | Breast Cancer | - | - |
EC chemotherapy | Phase 2 | Breast Cancer Invasive | - | - |
HRS-4642+AG +Adebrelimab | Phase 2 | Pancreatic Cancer | - | - |
COPOX | Phase 2 | Gastric Cancer (GC) | - | - |
Mecapegfilgrastim, day 2 | Phase 2 | Multiple Myeloma | - | - |
Radiation | Phase 2 | Esophageal Neoplasms | - | - |
TACE with adebrelimab and bevacizumab | Phase 2 | Adebrelimab | - | - |
Cetuximab Solution for Infusion | Phase 2 | Advanced KRAS G12D Mutant Solid Tumors | - | - |
SHR-9839 | Phase 2 | Advanced KRAS G12D Mutant Solid Tumors | - | - |
HRS-4508+ Trastuzumab+ Pertuzumab | Phase 2 | Solid Tumor | - | - |
HRS-4508+ Trastuzumab + Nab-paclitaxel | Phase 2 | Solid Tumor | - | - |
HRS-4508+SHR-A1811 | Phase 2 | Solid Tumor | - | - |
HRS-2189 Tablets | Phase 2 | Breast Cancer | - | - |
SHR2554; SHR-1701 | Phase 2 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | - | - |
Mecapegfilgrastim, day 5 | Phase 2 | Multiple Myeloma | - | - |
Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection | Phase 2 | Advanced KRAS G12D Mutant Solid Tumors | - | - |
Fluzoparib | Phase 2 | Metastatic Castration Resistant Prostate Cancer | - | - |
HRG2010(II) | Phase 2 | Parkinson's Disease | - | - |
• Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
HRS-9190; under Intravenous Anesthesia | Phase 2 | Neuromuscular Blockade | - | - |
HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel | Phase 2 | Solid Tumor | - | - |
HRS-4508+ Trastuzumab+ Capecitabine | Phase 2 | Solid Tumor | - | - |
Letrozole Tablets | Phase 2 | Breast Cancer | - | - |
SHR2554; Adabelimumab | Phase 2 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | - | - |
HRS-4508+ Trastuzumab | Phase 2 | Solid Tumor | - | - |
Immunotherapy | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
Pyrotinib Maleate | Phase 2 | Breast Neoplasms | - | - |
SHR4640 ; Febuxostat | Phase 2 | Primary Gout and Hyperuricemia | - | - |
Herombopag | Phase 2 | Non Severe Aplastic Anemia | - | - |
SHR-A1811 Injection + Adebrelimab Injection | Phase 2 | HR Positive/HER2 Low Breast Cancer | - | - |
Doxorubicin Hydrochloride Liposome Injection | Phase 2 | Breast Cancer | - | - |
Dalpiciclib Isethionate Tablets | Phase 2 | Breast Neoplasms | - | - |
FH-006 for Injection | Phase 2 | Malignant Solid Tumor | - | - |
SHR-8068 | Phase 2 | Pancreatic Cancer | - | - |
Docetaxel Injection | Phase 2 | Prostate Cancer | - | - |
SHR2554 tablets | Phase 2 | Prostate Cancer | - | - |
SHR-A1904 Injection | Phase 2 | Advanced Gastric Cancer | - | - |
Abiraterone Acetate tablets（II） | Phase 2 | Prostate Cancer | - | - |
Prednisone Acetate tablets | Phase 2 | Prostate Cancer | - | - |
HRS-6208 capsules | Phase 2 | Prostate Cancer | - | - |
SHR-1701 Injection | Phase 2 | Advanced Gastric Cancer | - | - |
SHR-1316 | Phase 2 | Small Cell Lung Cancer | - | - |
SHR0302 Base Gel | Phase 2 | Non-segmental Vitiligo | - | - |
Dalpiciclib | Phase 2 | Breast Cancer | - | - |
exemestane, fulvestrant, letrozole, tamoxifen | Phase 2 | Metastatic Breast Cancer | - | - |
SHR-A1811 combined with other antitumor therapies | Phase 2 | HER2-expressing Advanced Solid Tumors | - | - |
Camrelizumab plus apatinib Cohort B | Phase 2 | Gestational Trophoblastic Neoplasia | - | - |
SHR-1316 Injection | Phase 2 | Malignant Solid Tumor | - | - |
Letrozole or anastrozole or Fulvestrant | Phase 2 | Advanced Breast Cancer | - | - |
Inetetamab | Phase 2 | Breast Neoplasms | - | - |
GEMOX | Phase 2 | Advanced Primary Liver Cancer | - | - |
CAPOX | Phase 2 | CRC (Colorectal Cancer) | - | - |
Bupivacaine Liposome Injection | Phase 2 | Local Analgesia Via Nerve Block | - | - |
SHR-A1904 or/and HRS-4642 | Phase 2 | Pancreatic Cancer | - | - |
SHR-A2102, HRS4642 and Adebrelimab | Phase 2 | Pancreatic Cancer | - | - |
SHR-A1811 or/and HRS-4642 | Phase 2 | Pancreatic Cancer | - | - |
Propofol Injection | Phase 2 | Local Anesthesia Assisted Sedation | - | - |
RSS0343 Tabella | Phase 2 | Adolescent Asthma | - | - |
SHR-1020 | Phase 2 | Recurrent or Metastatic Cervical Cancer | - | - |
SHR-3167 Injection | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
HRS-4508+ Capecitabine | Phase 2 | Solid Tumor | - | - |
SHR2554/CHOP | Phase 2 | Peripheral T-cell Lymphoma | - | - |
SP2086/Metformin | Phase 2 | Type 2 Diabetes | - | - |
Retlirafusp alfa Injection | Phase 2 | CRC (Colorectal Cancer) | - | - |
KN019 | Phase 2 | Rheumatoid Arthritis | - | - |
HR18042 | Phase 2 | Moderate to Severe Acute Pain | - | - |
KN026 | Phase 2 | Gastric/Gastroesophageal Junction Cancer | - | - |
SHR-1701 | Phase 2 | Pancreatic Cancer | - | - |
SHR117887 | Phase 2 | Type 2 Diabetes | - | - |
FOLFOX4 | Phase 2 | Advanced Primary Liver Cancer | - | - |
FH-006; SHR-1316 ; SHR-8068 | Phase 2 | Lung Cancer | - | - |
Abiraterone Tablet | Phase 2 | Prostate Cancer | - | - |
SS109 | Phase 2 | Male | - | - |
SHR2554 Tablet | Phase 2 | Prostate Cancer | - | - |
Darotamine Capsule | Phase 2 | Prostate Cancer | - | - |
FH-006 ; SHR-1316 ; BP102 | Phase 2 | Lung Cancer | - | - |
SHR3680 Tablet | Phase 2 | Prostate Cancer | - | - |
HRS-1167 tablets | Phase 2 | Prostate Cancer | - | - |
HRS4800 tablets | Phase 2 | Pain | - | - |
Fluzoparib+Apatinib | Phase 2 | Relapsed Ovarian Cancer | - | - |
HR19042 Capsules | Phase 2 | IgA Nephropathy | - | - |
FRSW117 | Phase 2 | Severe Hemophilia A | - | - |
HRS-4508 tablet | Phase 2 | Lung Cancer | - | - |
Famitinib | Phase 2 | Colorectal Cancer | - | - |
HRG2010(I) | Phase 2 | Parkinson's Disease | - | - |
SHR0302 Tablets | Phase 2 | Non-segmental Vitiligo | - | - |
APL-1202 treatment | Phase 2 | Non-muscle Invasive Bladder Cancer | - | - |
KN026 combination | Phase 2 | HER2-positive Solid Tumors | - | - |
mFOLFIRINOX | Phase 2 | Advanced Pancreatic Cancer | - | - |
HS-20093 for Injection | Phase 2 | Prostate Cancer | - | - |
benzbromarone | Phase 2 | Hyperuricemia | - | - |
JSKN016 | Phase 2 | Inoperable Locally Advanced HER2-Negative Breast Cancer | - | - |
HS-20004 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
HRS-6209 Capsules | Phase 2 | Breast Cancer | - | - |
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin | Phase 2 | Lung Cancer | - | - |
HR021618 | Phase 2 | Pain After Abdominal Surgery | - | - |
HRS-5041 tablets | Phase 2 | Prostate Cancer | - | - |
HS-10375 | Phase 2 | Advanced or Metastatic NSCLC | - | - |
HS-10365 capsules | Phase 2 | Nonsmall Cell Lung Cancer | - | - |
SHR7280 | Phase 2 | Endometriosis | - | - |
SHR-A1811 combined with Pyrotinib | Phase 2 | HER2-expressing Advanced Solid Tumors | - | - |
HS-20094 | Phase 2 | Type 2 Diabetes | - | - |
SP2086 | Phase 2 | Type 2 Diabetes | - | - |
HRS-6209 in Combination with Fulvestrant | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
SHR2554; SHR-A2102 | Phase 2 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | - | - |
Insulin Degludec | Phase 2 | Type 2 Diabetes | - | - |
SHR-1703 | Phase 2 | Asthma With Eosinophilic Phenotype | - | - |
mFOLFOX7 combined with Camrelizumab and apatinib | Phase 2 | Hepatocellular Carcinoma Non-resectable | - | - |
Paclitaxel for injection (albumin-bound) | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
KN046 | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
SHR-3167 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
SHR 1210+apatinib | Phase 2 | Hepatocellular Carcinoma | - | - |
SHR0302Base gel | Phase 2 | Vitiligo | - | - |
SHR-A1904 | Phase 2 | Advanced Solid Tumors | - | - |
HRS-6768 | Phase 2 | Advanced Solid Tumors | - | - |
SHR- A1811 | Phase 2 | Gynaecological Malignancies | - | - |
Meropenem | Phase 2 | Hospital-acquired Bacterial Pneumonia (HABP) | - | - |
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection) | Phase 2 | Advanced Non-small Cell Lung Cancer | - | - |
SHR-4394 | Phase 2 | Prostate Cancer | - | - |
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 | Phase 2 | Advanced Non-small Cell Lung Cancer | - | - |
SHR-1314 | Phase 2 | Moderate-to-severe Chronic Plaque Psoriasis | - | - |
HR020602 injection | Phase 2 | Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol) | - | - |
HRS-6213 | Phase 2 | Patients With Solid Tumors | - | - |
Camrelizumab、Rivoceranib | Phase 2 | Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | - | - |
HRS-9190; under Inhalational Anesthesia | Phase 2 | Neuromuscular Blockade | - | - |
HRS-8364 Tablet | Phase 2 | Solid Tumor | - | - |
Advanced Primary Liver Cancer
1 drug in this indication
CRC (Colorectal Cancer)
1 drug in this indication
Primary Gout and Hyperuricemia
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's drug pipeline?→
CatalystAlert tracks 240 drug candidates in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JHPCY) pipeline across Phase 3, Phase 2. Its lead program is HS-20093 for Injection (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's next FDA catalyst?→
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JHPCY) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JHPCY biotech catalysts?→
Add JHPCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.